Upon completion of both tranches, PharmaDrug will hold a 40% interest in Canurta, and Canurta limited partners will hold approximately 44% of PharmaDrug's issued and outstanding shares on a pro forma ...
Mr. Dewhurst Brings Over 30 Years of Life Sciences and M&A Experience to the Board, Aligning with the Company’s Strategic Long-Term Goals for Growth and Expansion LOS ANGELES, Jan. 07, 2026 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback